FY2025 · ended Dec 31, 2025 · Revenue $616.29M, +87.3% YoY · Filed Feb 27, 2026
TG Therapeutics, Inc. (TGTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $616.3 million and net income of $447.2 million. Free cash flow was -$25.0 million. As of Jun 30, 2026 it held $616.6 million in cash and investments and $754.4 million in total debt.
Revenue (TTM)
$799.54M
+76.1% vs year-ago TTM
Net income (TTM)
$441.49M
+630.2% vs year-ago TTM
Operating cash flow (TTM)
$17.88M
+130.2% vs year-ago TTM
Free cash flow (TTM)
$17.39M
EPS (TTM)
$2.77
+672.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
159.69M
+1.7% vs prior year
Net cash
$-137.82M
as of Jun 30, 2026
Operating margin
17.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TGTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1001316
- Former names
- MANHATTAN PHARMACEUTICALS INC (until Apr 27, 2012); ATLANTIC TECHNOLOGY VENTURES INC (until Mar 10, 2003); ATLANTIC PHARMACEUTICALS INC (until Feb 4, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M |
| Net income | $447.2M | $23.4M | $12.7M | — | — |
| Diluted EPS | $2.77 | $0.15 | $0.09 | -$1.65 | — |
| Operating cash flow | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M |
| Total assets | $1.1B | $577.7M | $329.6M | $193.6M | $379.6M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M |
| Stockholders' equity | $648.0M | $222.4M | $160.5M | — | — |
| Cash and investments | $201.1M | $311.8M | $217.5M | $174.1M | $350.3M |
| Total debt | $253.7M | $253.7M | $111.1M | $83.1M | $79.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Other events
|
Jun 3, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Other events
|
May 27, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 1000 TG Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.